Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study-Reference-Cited by-同舟云学术

Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study

Published:2017-12-20 Issue:2 Volume:9 Page:278-283
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Shi Qingming¹^ORCID,Guan Maojing¹,Wang Yong²,Xu Congjing³,Tang Lei⁴,Fu Wenhua⁵,Bi Minghong⁶,Sun Xiang⁷,Gu Kangsheng⁸,Pang Dongsheng⁹

Affiliation:

1. Department of Oncology; Anhui Chest Hospital; Hefei China

2. Department of Oncology; Anhui Provincial Hospital; Hefei China

3. Department of Oncology; Huainan East Hospital; Huainan China

4. Department of Oncology; Anhui No 2. Province People's Hospital; Hefei China

5. Department of Oncology; Chaoyang Hospital; Beijing China

6. Department of Oncology; The First Affiliated Hospital of Bengbu Medical College; Bengbu China

7. Department of Oncology; Hefei First People's Hospital; Hefei China

8. Department of Oncology; The First Affiliated Hospital of Anhui Medical University; Hefei China

9. Department of Oncology; Anqing Naval Hospital; Anqing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12577/fullpdf

Reference20 articles.

1. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: A retrospective analysis for 1660 Japanese patients;Inoue;Jpn J Clin Oncol,2016

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

4. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS);Fukuoka;J Clin Oncol,2011

5. First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung;Han;J Clin Oncol,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer;Medicine;2022-11-25

2. Effects of WSG, a polysaccharide from Ganoderma lucidum, on suppressing cell growth and mobility of lung cancer;International Journal of Biological Macromolecules;2020-12

3. Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer;Clinical Lung Cancer;2020-11

4. Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series;Thoracic Cancer;2020-04

5. Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation;International Journal of Cancer;2019-01-03